Replies to post #321 on UniCycive Therapeutics Inc (UNCY)

[Whalatane]

It also showed Net Loss:

Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million,

They will have lost at least another $20m-$28m due to running this trial etc in Q2.
So they are down to around 1 qtr cash on hand unless they drastically cut expenses and raise some funds

The CC cut off on me but during the Q & A I think they were trying to explain why 106 were enrolled but only 71 ?? were evaluated . That would create a sell first and ask questions later market reaction .
I'll try and listen to it again

Kiwi